This month, the Sabin Vaccine Institute will begin a Phase-1 clinical trial in Washington, DC to further investigate the Na-GST-1 human hookworm vaccine candidate. The trial is being conducted in collaboration with George Washington University and the Children’s National Medical Center, and volunteers are currently being recruited.
The purpose of the trial is to determine the best formulation of the vaccine to be used in future clinical trials. It is being conducted concurrently with the Phase 1 trial that began in January 2012 in Brazil. Ultimately the vaccine will be tested in children in hookworm endemic areas, the target population for the hookworm vaccine.
More than 500 million people in developing countries are affected by hookworm. These vaccine trials have the potential to prevent disease and positively impact the lives of a huge number of people.
To learn more about volunteering/participating, click here.